NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 11/3/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and TrendsSEC Filings About ZyVersa Therapeutics Stock (NASDAQ:ZVSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZyVersa Therapeutics alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range$0.00▼$0.1152-Week Range$0.00▼$0.30Volume20 shsAverage Volume31,029 shsMarket Capitalization$7.94 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company developing therapies for renal and inflammatory diseases. The company focuses on conditions in which abnormal lipid accumulation, inflammation and immune-system activity contribute to disease progression. ZyVersa’s pipeline includes VAR 200, an investigational cholesterol efflux mediator being developed for kidney disorders such as focal segmental glomerulosclerosis and diabetic kidney disease. The company is also developing IC 100, an investigational inflammasome inhibitor designed to target NLRP3-driven inflammation and potentially address a range of inflammatory diseases. The company is headquartered in Weston, Florida, and was founded in 2014. ZyVersa is led by co-founder Stephen C. Glover, who serves as chairman and chief executive officer. Its development programs are intended for patients with serious diseases for which additional treatment options are needed.AI Generated. May Contain Errors. Read More Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVSA Stock News HeadlinesZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Corporate Event Calendar | OTC:ZVSAJuly 27, 2026 | benzinga.comZyVersa Therapeutics Transitions to OTC Pink MarketJuly 17, 2026 | tipranks.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | Decentralized Masters (Ad)ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 13, 2026 | globenewswire.comZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comZyversa Therapeutics Faces Financial Challenges Amid Drug DevelopmentNovember 20, 2025 | msn.comZyVersa Therapeutics Reports Third Quarter 2025 Financial ResultsNovember 19, 2025 | globenewswire.comZyVersa Therapeutics Delays 10-Q FilingNovember 14, 2025 | tipranks.comSee More Headlines ZVSA Stock Analysis - Frequently Asked Questions How have ZVSA shares performed this year? ZyVersa Therapeutics' stock was trading at $0.1336 at the start of the year. Since then, ZVSA shares have decreased by 99.3% and is now trading at $0.0010. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.33. When did ZyVersa Therapeutics' stock split? Shares of ZyVersa Therapeutics reverse split on Friday, April 26th 2024.The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ZyVersa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZyVersa Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Enphase Energy (ENPH), Ensysce Biosciences (ENSC), Cybin (HELP), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/12/2025Today11/05/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZVSA CIK1859007 Weblsprhealth.com Phone754-231-1688FaxN/AEmployees2Year Founded2014Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-109.54% Return on Assets-43.95% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book0.00Miscellaneous Outstanding Shares7,936,000Free Float4,863,000Market Cap$7.94 thousand OptionableNot Optionable Beta0.87 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZVSA) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVSA Stock Alerts